Neutralizing monoclonal antibodies for early treatment of hospital‐acquired SARS‐CoV‐2 infection in hematologic patients

Efficacy of early treatment with anti‐SARS‐CoV‐2 spike protein monoclonal antibodies (mAbs) for nosocomial SARS‐CoV‐2 infection in hematologic patients is unknown. Retrospective, cohort study conducted in four Italian teaching hospitals. We included adult patients with hematologic malignancies and hospital‐acquired SARS‐CoV‐2 infection diagnosed between November 2020 and December 2021. The principal exposure variable was administration of mAbs. The primary endpoint was clinical failure dea composite outcome of mortality and/or invasive and noninvasive ventilation within 90 days from infection onset. We included 52 patients with hospital‐acquired SARS‐CoV‐2 infection. Males were 29 (60%), median age was 62 (interquartile range [IQR] 48–70). Forty‐five (86%) patients were on chemotherapy or had received chemotherapy within 30 days. MAbs were administered in 19/52 (36%) patients. Clinical failure occurred in 22 (42%) patients; 21% (4/19) in mAbs group versus 54% (18/33) in non‐mAbs group ( p = 0.03). Other predictors of clinical failure were older age (median [IQR] 69 [61–72] versus 58 [46–66], p = 0.001), and higher Charlson comorbidity index (median [IQR], 5 [3.25‐5] versus 3 [2–5], p = 0.002). At multivariable Cox regression model, mAbs were independently associated with a significantly lower rate of clinical failure (HR 0.11, 95% CI 0.01–0.85, p = 0.01), after adjusting for confounders. In conclusion, mAbs are promising for early treatment of hematologic patients with healthcare‐related SARS‐CoV‐2 infection.

show abstract

Neutralizing monoclonal antibodies for early treatment of hospital‐acquired SARS‐CoV‐2 infection in hematologic patients

Bussini

Testi

Tazza

et al. 2022

eJHaem

Self Cite

View full text Add to dashboard Cite

show abstract

Early COVID‐19 treatment with Sotrovimab in high‐risk Beta‐thalassemia: Real‐life case‐series, state of the art and new perspectives

Torti

2023

Br J Haematol

View full text Add to dashboard Cite

Dear Editor, This report aims to provide a clinical demonstration of the safety and effectiveness of sotrovimab, regarding our experience in using this preventative therapy, with real-world data, which are scarce and sometimes conflicting during the different waves of the pandemic.Neutralizing monoclonal antibodies (mAbs) have been shown to reduce COVID-19 severity in patients with underlying predisposing conditions. mAbs such as sotrovimab, casirivimab/imdevimab and bamlanivimab/etesevimab are effective at reducing the risk of subsequent hospitalization in COVID-19 outpatients and have since received US Food and Drug Administration (FDA) emergency-use authorization for this indication 1,2 (Table 1).Sotrovimab is a pan-sarbecovirus mAb useful to prevent the progression of COVID-19 in high-risk patients. To date, little is known about the efficacy, tolerability and indications of mAbs in thalassaemia patients with COVID-19.The prevalence of SARS-CoV-2 infection among beta (β) thalassaemia seems to be lower than the general population, however, associated comorbidities confer the risk of more severe disease, with a fivefold increase in age-standardized lethality. 3,4 Considering the position statement of the Thalassaemia International Federation (TIF), the highest risk group for severe infectious complications, included thalassaemia patients with splenectomy and one or more severe systemic diseases, underlying comorbidities such as diabetes, cardiac, endocrine, hepatic or respiratory disease, severe iron overload, age more than 50 years and suboptimal haemoglobin pretransfusional level (less of 7 g/dL). 5 We conducted a retrospective cohort study of all adult βthalassaemia patients who acquired SARS-CoV-2 infection in February 2020 up to March 2023. We describe the clinical outcome of 54 β-thalassaemia patients, who were infected by the SARS-CoV-2 virus (Supplementary Video S1). The majority of them (51) have received mRNA vaccines, and only three have not been vaccinated by their own choice.The patients included in this study were diagnosed with SARS-CoV-2 infection diagnosed between February 2020 and March 2023. Sotrovimab was administered to three patients based on clinical features as well as comorbidities and drug-drug interactions, and on the availability of this drug,

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Neutralizing monoclonal antibodies for early treatment of hospital‐acquired SARS‐CoV‐2 infection in hematologic patients

Cited by 2 publications

References 22 publications